Kintor Pharmaceutical (HKG:9939) completed the enrollment of the first subject in the phase 3 stage pivotal clinical trial of its KX-826 tincture 1% for treating male adult hair loss, specifically the androgenetic alopecia, in China.
The trial is a multi-center, randomized, double-blind, vehicle-controlled study and adopts a 2-in-1 design for the evaluation of efficacy and safety of KX-826 tincture 1.0% for the treatment of hair loss, a Monday Hong Kong bourse filing said.
The phase 3 trials are expected to enroll 666 patients in China within five months in 25 clinical research centers in the country.
The trial comprises a 24-week treatment phase followed by a month of safety observation, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。